Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab for EBV-HLH and CAEBV
NCT05384743Phase 3Unknown
- Sponsor
- Beijing Friendship Hospital
- Start
- Feb 2022
- Primary completion
- Feb 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rituximab in hemophagocytic lymphohistiocytosis (HLH) and chronic active Epstein-Barr virus infection (CAEBV), sponsored by Beijing Friendship Hospital. Primary endpoint: Epstein-Barr Virus DNA Load at 8 weeks. Status: unknown.
02
Drugs
rituximab
03
Conditions
hemophagocytic lymphohistiocytosis (HLH)chronic active Epstein-Barr virus infection (CAEBV)
Beyond the preview
Go deeper on NCT05384743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05384743.